Therapeutic hopes arising from preclinical models in transplantation and autoimmune diseases (rheumatoid polyarthritis, psoriasis,…)
In transplantation models performed in vivo (heart3-5, liver6 and kidney,7,8 transplants), CD28 antagonists act in synergy with other products (monoclonal antibodies and calcineurin inhibitors [CNI]). The CNI product class is the treatment of reference, with its leader cyclosporine, often combined with corticoids. Allo-reactivity or graft rejection are inhibited by FR104. Regulatory T cells are induced around and inside the graft and enable compelling graft results on the long term. When associated to calcineurin (without corticoids added, or low dose CNI), FR104 is able to prevent graft rejection, to inhibit the development of alloantibodies and to extend graft survival13 on the long term.
Other models of autoimmune diseases performed in vivo have clearly demonstrated the efficacy of FR104 [encephalomyelitis14, rheumatoid polyarthritis (Vierboom et al, 2016), uveitis10, psoriasis11]. They have confirmed the therapeutic high potential of this anti-CD28 monoclonal antibody.